Eisenmenger Syndrome: Recent Advances in Pharmacotherapy

Title:Eisenmenger Syndrome: Recent Advances in Pharmacotherapy

Volume: 11 Issue: 4

Author(s): Sarmad Said, Mateo Porres-Aguilar, Mateo Porres-Munoz and Debabrata Mukherjee

Affiliation:

Keywords: Congenital heart disease, endothelin receptor antagonists, eisenmenger syndrome, phosphodiesterase type-5 inhibitors, prostanoids, pulmonary arterial hypertension.

Abstract: Over the last decade advanced therapies for the management of pulmonary arterial hypertension have been introduced. These agents have also been effective in reducing pulmonary vascular resistance in patients with Eisenmenger syndrome. Specific guidelines focusing on modern therapies for Eisenmenger syndrome however do not exist to date. More recently, clinical trials in patients with Eisenmenger syndrome demonstrated a significant clinical improvement with favorable safety and tolerability profile. This review aims to summarize newly reported pharmacological agents used in patients with Eisenmenger syndrome.

Cite this article as:

Said Sarmad, Porres-Aguilar Mateo, Porres-Munoz Mateo and Mukherjee Debabrata, Eisenmenger Syndrome: Recent Advances in Pharmacotherapy, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (4) . https://dx.doi.org/10.2174/1871525712666140321095519